NervGen Pharma Corp. is a junior biotechnology company that operates in the healthcare sector. NervGen Pharma innovates and develops biotech solutions to treat nerve damage due to neurodegenerative diseases, physical injury, or other medical problems.
NervGen Pharma Corp. is a public Toronto Venture Stock Exchange company with its stocks listed under the symbol NGEN. The pharmaceutical company also trades its stocks on the OTCQX market under the stock symbol NGENF.
The Vancouver-based healthcare company is developing NVG-291, a potential drug candidate to cure nerve damage or neurodegenerative diseases, such as Alzheimer's disease, spinal cord injuries and multiple sclerosis. The technology by NervGen Pharma Corp. is focused on a novel receptor known as protein tyrosine phosphate sigma (PTPσ) that slows nerve damage, enables the regeneration of damaged nerves, and enhances the function or performance of nerves.
In a press release dated June 25, 2021, NervGen Pharma Corp. employed Vorticom Inc., a fully integrated public relations company based in New York, to manage media relations and other such services on behalf of the company.
On July 15, 2021, the company established the Multiple Sclerosis Clinical Advisory Board comprising six members engaged in scientific and clinical research work to develop medical solutions for multiple sclerosis. The purpose of the Board is to work with and assist the company in the future clinical test phase of its lead drug candidate NVG-291.
In a press release dated August 9, 2021, NervGen Pharma Corp. reported that it collaborated with Massachusetts General Hospital (MGH) to conduct preclinical studies of NVG-291 on valid animal models for the treatment of Alzheimer's disease. The president and Chief Executive Officer of NervGen Pharma Corp., Paul Brennan, expects that phase 1b clinical studies of NervGen's lead compound for Alzheimer's disease in patients would begin in 2022.